Loading
A phase 1/2 trial of Trastuzumab, Pertuzumab, Oxaliplatin, Capecitabine, Ramucirumab and Bevacizumab in advanced solid tumours, run by FBD Biologics Limited, active and no longer recruiting.
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06771622 by FBD Biologics Limited, with 500 participants enrolled, started 2025-03-13 and due to reach its primary completion in 2028-01-01. Interventions recorded: HCB101, Trastuzumab, Pertuzumab, Oxaliplatin, Capecitabine and Ramucirumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pertuzumab, Trastuzumab, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pertuzumab, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Bevacizumab, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pertuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Trastuzumab, Capecitabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/